

Curriculum Vitae Europass



Date 12/10/2025
Name(i) / Surname(i) **Michelangelo Fiorentino**
E-mail michelangelo.fiorentino@unibo.it
Citizenship Italy

Current Position Full professor of Pathology, Alma Mater Studiorum University of Bologna
 Director, Pathology Service Maggiore Hospital, AUSL of Bologna.

Professional experience

- 2000 Freelance pathologist at the Pathology Service, Addarii Institute of Oncology, S.Orsola-Malpighi Teaching Hospital, University of Bologna
- April 2001- December 2007. Staff pathologist at the Pathology Service, Addarii Institute of Oncology, S.Orsola-Malpighi Teaching Hospital, University of Bologna
- 2008 Staff Pathologist and Associate Director, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Harvard University, Boston, USA
- 2009 to 2019: Chief of the Unit Laboratory of Oncologic and Transplantation Molecular Pathology and responsible for the Genito-Urinary pathology at the Pathology Service, Addarii Institute of Oncology, S.Orsola-Malpighi Teaching Hospital, University of Bologna
- 2010-present Adjunct Associate Professor, Department of Epidemiology, T.Chan Harvard School of Public Health, Boston.
- 06-02-2017 to 30-09-2025 - Associate Professor of Pathology, University of Bologna
- 1-10-2025 present Full Professor Of Pathology University of Bologna
- 15/07/2019 to present Director Pathology Service Maggiore Hospital, AUSL of Bologna

Teaching experience

- Since 2010 Adjunct Assistant Professor and since 2018 Adjunct Asso-

	ciate Professor, Department of Epidemiology, T.Chan Harvard School of Public Health, Boston. Course title "Pathology for Epidemiologists" 1.25 credits, years 2010-2023. • 2017-2019 Associate Professor of Clinical Pathology, University of Bologna, Schools of Medicine and Biotechnology • Since 2019 Associate Professor of Pathology, University of Bologna, Schools of Medicine and Biotechnology teaching the following courses: - Bone and Joints Pathology, School of Medicine and Surgery 1 credit - Abdominal Pathology, School of Medicine and Surgery 2 credits - Diagnostic Molecular Pathology, School of Biotechnology, 6 credits - Histopathology, School of Bio-medical Technician 2 credits - Anatomic Pathology, School of Medicine - Molecular Biology, Residency program in Radiation Therapy, 1 credit - Genito-Urinary Pathology, Residency program in Pathology, 7 credits
Tutoring	Currently tutor of 5 pre-doctoral students Previous tutor of 28 pre-doctoral and 1 doctoral students
Awards	• 1995 Young Investigator Award of the Italian Association for Cancer Research (AIRC). • 2000 Pezcoller Young Investigator Award at the 91° Meeting of the American Association for Cancer Research (AACR), S.Francisco, U.S.A. April 1-4 2000.
Professional associations/ Editorial Boards	• Member (#13193), American Association for Cancer Research since 1995 • Member (#2029722) United States and Canadian Academy of Pathology since 2008 • Member of the Editorial Board of the AACR Journals Clinical Cancer Research and Molecular Cancer Research • Member GenitoUrinary Pathology Society (GUPS) • Member European Society of Urothology (ESUP)
Education	• 1986: <u>Classic High School</u> at Liceo-Ginnasio "L.Galvani", Bologna. • 1992: <u>Degree in Medicine</u>, vote 110/110 cum laude at the University of Bologna, Italy. • 1994-1995 Fellowship at the laboratory of Molecular Pathology, Pathology Dept. New England Deaconess Hospital, Harvard Medical School, Boston, USA. Supervisor Massimo Loda MD • 1996 <u>PhD</u> with best evaluation in "General and applied biology of the GI tract tumors" at the University of Modena, Italy • 2000: Residency in Diagnostic Oncology, vote 70/70 cum laude at the Residency program of Diagnostic Oncology, University of Bologna, Italy. (The

Sign-out activity

residency in Diagnostic Oncology was equivalent to the Residency in Pathology for the access to staff positions in pathology for the Italian National Health Service)

Personal skills

I'm a genito-urinary and a molecular pathologist with particular diagnostic experience in solid tumors and genitor-urinary pathology. I practiced himself in the following molecular pathology techniques: immunohistochemistry, Western blot, in situ hybridization chromogenic and fluorescent; real time PCR Laser Capture Microdissection, digital image analysis. I sign out most of the genito-urinary pathology performed in my laboratory and I have been involved in several clinical trials on solid tumors as reference pathologist. I have been international official reviewer of several prostate cancer cohorts with the Channing Laboratory, T. Chan Harvard School of Public Health, the Universities of Orebro and the Karolinska Institutet in Sweden. I have been consultant for the Regione Emilia-Romagna and the Italian Ministry of Health for the issues regarding nomenclature and reimbursement of molecular diagnostic tests. I participated into clinical studies according to GCP guidelines.

Funded Grants (last 10 years)

- P.I. SA43FIOR SSN grant "Clinical impact of mutational analysis of KRAS, BRAF, EGFR and PIK3CA in personalized therapy of solid tumors" 2010-2012 , € 70.000
- P.I. Region-University grant Region Emilia-Romagna "Optimizing molecular tests for the genes HER2, KRAS, EGFR in patients with solid tumors candidates to personalized oncologic treatments" 2011-2013" € 240.900
- Collaborator "18F-FACBC PET/CT for staging high risk prostate cancer" REGIONE EMILIA-ROMAGNA, PROGETTI UNIVERSITA'-REGIONE. 2014-2016
- Co-investigator Molecular classification of hepatocellular carcinoma to select the more appropriate surgical treatment: liver transplantation or liver resection" REGIONE EMILIA-ROMAGNA, PROGETTI UNIVERSITA'-REGIONE € 72.000
- Co-investigator. "Use of biomarkers and gene expression profiles to identify cancer patients with different prognosis and sensitivity to molecular targeted agents" REGIONE EMILIA-ROMAGNA, PROGETTI UNIVERSITA'-REGIONE 2013-2016 € 33.000
- Co-investigator "PROMORT, prostate cancer mortality" University of Orebro, Karolinska Institutet, Svezia 2015-2018 € 106.000
- Co-investigator CARATTERIZZAZIONE MOLECOLARE AVANZATA DI TUMORI SOLIDI AVANZATI CONDIDATI AL TRATTAMENTO CON TERAPIE MIRATE INNOVATIVE " Bando Fondazione del Monte di Bologna e Ravenna;2017 € 33.000
- Co-investigator "Study of PD-L1 and other immunotherapy efficacy predictors on cytology and circulating tumor cells in advanced NSCLC" AIRC Investigator Grant PI A. Ardizzoni 2017-2019, € 470.000
- 2020 ProgettoOrganizzazione e gestione dei percorsi formativi di re-training rivolti agli operatori cito-i-stologici per la promozione della qualità dei programmi di screening. REGIONE EMILIA-ROMAGNA, PIANO REGIONALE DELLA PREVENZIONE Ruolo: Principal Investigator Finanziamento Euro 12.000

Lice
nsur
es

Publ
icati
ons

- 2021-2022 Progetto "Controllo di qualità istologico e immunoistochimico delle lesioni serrate del colon e dei tumori colorettali con instabilità micro satellitare. REGIONE EMILIAROMAGNA, PIANO REGIONALE DELLA PREVENZIONE Ruolo: Principal Investigator Finanziamento Euro 16.000

- 2022-2024 Progetto "Patho-epidemiological association of male sex, prostate cancer and lethality from Sars Cov-2" REGIONE EMILIA-ROMAGNA BANDO RICERCA FINALIZZATA BOTTOM UP Ruolo: Principal Investigator Finanziamento Euro 184.000

- 1992. Board certified M.D. enrolled in the Medical Registry of Bologna, Italy. Registration number 12600

- January 2016. Managing certification for the habilitation to direct direct complex health structures, released by the Emilia-Romagna Region in name of the Italian Ministry of Health

- Certificate of Completion of "GCP compliance training for HCPs V2.0. Nov 7th 2017

I am author or co-author of 346 full papers on peer-reviewed international journals

H index = 57 (according to Scopus)

Publications 2020-2025

1: Melotti S, Ambrosi F, Franceschini T, Giunchi F, Vasuri F, Orsatti A, Di

Sciascio L, Grillini A, Franchini E, Massari F, Mollica V, Marchetti A, Mineo

Bianchi F, Colecchia M, Acosta AM, Lobo J, Fiorentino M, Ricci C.

Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors. Am J Clin Pathol. 2025 Sep 17;aqaf098. doi: 10.1093/ajcp/aqaf098. Epub ahead of print. PMID: 40972670.

2: Ricci C, Ambrosi F, Franceschini T, Grillini A, Franchini E, Vasuri F,

Orsatti A, Di Sciascio L, Massari F, Mollica V, Marchetti A, Bianchi FM,

Colecchia M, Acosta AM, Lobo J, Fiorentino M. Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study. Virchows Arch. 2025 Sep 11. doi: 10.1007/s00428-025-04243-x. Epub ahead of print. PMID: 40936013.

3: Ricci C, Di Sciascio L, Ambrosi F, Grillini M, Mollica V, Massari F,

Fiorentino M, De Leo A, Idrees MT, Ulbright TM, Acosta AM. Correction to: The absence of FOXA2 and HNF1 β expression in vasculogenic mesenchymal lesions of germ cell origin suggests an evolutionary pathway similar to that of sarcomatoid yolk sac tumor. Virchows Arch. 2025 Sep 5. doi: 10.1007/s00428-025-04261-9. Epub ahead of print. Erratum for: Virchows Arch. 2025 Aug 18. doi: 10.1007/s00428-025-04223-1. PMID: 40911190.

4: Ulvskog E, Kirrander P, Persson EK, Lillsunde-Larsson G, Dorofte L,

Franceschini T, Fiorentino M, Davidsson S. Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer. Eur Urol Open Sci. 2025 Aug 9;79:102-110. doi: 10.1016/j.euros.2025.07.012. PMID: 40822998; PMCID: PMC12357277.

5: Ricci C, Di Sciascio L, Ambrosi F, Grillini M, Mollica V, Massari F, Fiorentino M, De Leo A, Idrees MT, Ulbright TM, Acosta AM. The absence of FOXA2 and HNF1 β expression in vasculogenic mesenchymal lesions of germ cell origin suggests an evolutionary pathway similar to that of sarcomatoid yolk sac tumor. Virchows Arch. 2025 Aug 18. doi: 10.1007/s00428-025-04223-1. Epub ahead of print. Erratum in: Virchows Arch. 2025 Sep 5. doi: 10.1007/s00428-025-04261-9. PMID: 40820051.

6: Lianas L, Del Rio M, Pireddu L, Aspegren O, Giunchi F, Fiorentino M, Leo S, Zelic R, Vincent PH, Destefanis N, Zugna D, Richiardi L, Pettersson A, Akre O, Frexia F. An open-source platform for structured annotation and computational workflows in digital pathology research. Sci Rep. 2025 Aug 7;15(1):28910. doi: 10.1038/s41598-025-13546-7. PMID: 40775009; PMCID: PMC12331939.

7: Flanagan S, Lis RT, Huang Y, Jehane L, Vaselkiv JB, Allott EH, Finn SP, Lotan TL, Fiorentino M, Loda M, Lee GM, Chakraborty G, Kantoff PW, Mucci LA, Stopsack KH. Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer. Mol Cancer Res. 2025 Aug 5;10.1158/1541-7786.MCR-24-0864. doi: 10.1158/1541-7786.MCR-24-0864. Epub ahead of print. PMID: 40762635; PMCID: PMC12434729.

8: D'Annunzio G, Muscatello LV, Tugnoli C, Pesaro S, Luppi A, Fiorentino M, Franceschini T, Grillini A, Rugna G, Sarli G, Mandrioli L. Bright-Field Multiplex Immunohistochemistry in Swine PCV2 and PRRSV Lymphadenopathies. Animals (Basel). 2025 Jun 6;15(12):1682. doi: 10.3390/ani15121682. PMID: 40564235; PMCID: PMC12189695.

9: Bacci B, Martinoli G, Gallina L, Avallone G, Brunetti B, Franceschini T, Grillini A, De Biase D, Kapetanou A, Tura G, Sarli G, Balboni A, Fiorentino M, Ressel L. Immune cell analysis in equine penile papilloma, in situ squamous cell carcinoma and invasive squamous cell carcinoma: FoxP3+ T regulatory lymphocytes differ according to equine papillomavirus 2 status. Vet Pathol. 2025 May 26;3009858251341544. doi: 10.1177/03009858251341544. Epub ahead of print. PMID:

40417928.

10: Bianchi L, Cangemi D, Farolfi A, Sgro CMP, Giorgio AD, Castellucci P, Gaudio C, Corcioni B, Giunchi F, Degiovanni A, Pirelli V, Mignogna C, Rotaru V, Mottaran A, Piazza P, Droghetti M, Ragni M, Romei F, Mosconi C, Fiorentino M, Schiavina R, Fanti S, Brunocilla E. PSMA-Targeted Biopsy With Fusion Guidance for Detecting Clinically Significant Prostate Cancer in Men With Negative MRI-Feasibility and Diagnostic Performance of a Pilot Single-Center Prospective Study. Clin Genitourin Cancer. 2025 Jun;23(3):102348. doi: 10.1016/j.clgc.2025.102348. Epub 2025 Apr 4. PMID: 40312220.

11: Lin Z, Stopsack KH, Fiorentino M, Vaselkiv JB, Gerke T, Pettersson A, Flavin R, Flanagan S, Kantoff PW, Lotan TL, Preston MA, Finn SP, Loda M, Penney KL, Mucci LA. Long-term performance of the Gleason score in predicting metastatic and fatal prostate cancer. Am J Epidemiol. 2025 Apr 29;kwaf080. doi: 10.1093/aje/kwaf080. Epub ahead of print. PMID: 40302103.

12: Cavazzoni A, Digiaco G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, Giovannetti E, Fiorentino M, Tiseo M, Petronini PG, Ardizzoni A. Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> 2020, <i>12</i>, 666. Cancers (Basel). 2025 Apr 8;17(8):1254. doi: 10.3390/cancers17081254. Erratum for: Cancers (Basel). 2020 Mar 12;12(3):E666. doi: 10.3390/cancers12030666. PMID: 40282559; PMCID: PMC12025483.

13: Mottola M, Ricci C, Chiarucci F, Ravaioli C, Grillini A, Gherardi A, Fiorentino M, Bevilacqua A, Ambrosi F. Computer-Based Detection of Colorectal Serrated Lesions: Digital Flatness, a Novel Metric Designed for Whole-Slide Images. Lab Invest. 2025 Aug;105(8):104178. doi: 10.1016/j.labinv.2025.104178. Epub 2025 Apr 19. PMID: 40258493.

14: Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Danielli L, Maloberti T, Ricci C, Fiorentino M, Biase D, Massari F. Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience. Pathol Res Pract. 2025 Jun;270:155964. doi: 10.1016/j.prp.2025.155964. Epub 2025 Apr 9. PMID: 40233528.

15: Ricci C, Altavilla MV, de Biase D, Corti B, Pasquini E, Molteni G, Tarsitano A, Baietti AM, Amorosa L, Ambrosi F, Balbi T, Baldovini C, Querzoli G, D'Errico A, Fiorentino M, Tallini G, De Leo A, Maloberti T, Massi D, Ihrler S, Foschini MP. Unveiling the molecular landscape and clinically relevant molecular heterogeneity of mucosal melanoma of the head and neck region. Histopathology. 2025 Aug;87(2):270-283. doi: 10.1111/his.15456. Epub 2025 Apr 15. PMID: 40231352.

16: Ricci C, Melotti S, Di Sciascio L, Ambrosi F, Grillini M, Mollica V, Fiorentino M, De Leo A, Idrees MT, Ulbright TM, Acosta AM. Analysis of HNF1 β expression suggests that its downregulation is involved in the sarcomatoid transformation of yolk sac tumor. Virchows Arch. 2025 Feb 24. doi: 10.1007/s00428-025-04062-0. Epub ahead of print. PMID: 39992438.

17: Colecchia M, Fiorentino M, Ricci C, Tenace NP, Barella M, Pini GM. Sex Cord Stromal Tumors of the Testis: A Review with Molecular Updates. Surg Pathol Clin. 2025 Mar;18(1):75-89. doi: 10.1016/j.path.2024.08.009. Epub 2024 Sep 25. PMID: 39890311.

18: Eccher A, Marletta S, Pagni F, L'Imperio V, Piacentini F, Dominici M, Cavazza A, Pinto C, Brunelli M, Fiorentino M, Malapelle U, Baron MM, Martignoni G, Dei Tos AP. Automate the process of formalin-fixed paraffin-embedded blocks storage in the pathology laboratory: A proof of concept study. Pathol Res Pract. 2025 Feb;266:155802. doi: 10.1016/j.prp.2024.155802. Epub 2024 Dec 26. PMID: 39753016.

19: McGrath CB, Shreves AH, Shanahan MR, Guard HE, Nhliziyo MV, Pernar CH, Penney KL, Lotan TL, Fiorentino M, Mucci LA, Stopsack KH. Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors. Int J Cancer. 2025 May 15;156(10):1898-1908. doi: 10.1002/ijc.35279. Epub 2024 Dec 11. PMID: 39663641; PMCID: PMC11924303.

20: Magnani F, Demaria E, Ambrosi F, Sala C, Pasquinelli G, Fiorentino M, Gri G. The positive impact of virtual microscopy on histopathology education: a comparative, student-centered study. Adv Physiol Educ. 2025 Mar 1;49(1):136-146. doi: 10.1152/advan.00110.2024. Epub 2024 Nov 29. PMID: 39611369.

- 21: Di Sciascio L, Orsatti A, Ambrosi F, Franchini E, Massari F, Mollica V, Bianchi FM, Colecchia M, De Leo A, Acosta AM, Lobo J, Fiorentino M, Ricci C. Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel. Virchows Arch. 2025 Jul;487(1):221-226. doi: 10.1007/s00428-024-03911-8. Epub 2024 Sep 11. PMID: 39259293.
- 22: Ricci C, Ambrosi F, Grillini A, Grillini M, Mollica V, Fiorentino M, Sangoi AR, De Leo A, Idrees MT, Ulbright TM, Acosta AM. Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma. Histopathology. 2024 Oct;85(4):695-698. doi: 10.1111/his.15277. Epub 2024 Jul 1. PMID: 38952141.
- 23: Surucu A, de Biase D, Ricci C, di Sciascio L, Collins K, Idrees MT, Ebare K, Fiorentino M, Bridge JA, Ulbright TM, Acosta AM. Beta-Catenin Alterations in Postchemotherapy Yolk Sac Tumor, Postpubertal-Type With Enteroblastic Features. Mod Pathol. 2024 Jul;37(7):100513. doi: 10.1016/j.modpat.2024.100513. Epub 2024 May 17. PMID: 38763421.
- 24: Kitagawa Y, De Biase D, Ricci C, Cornejo KM, Fiorentino M, Collins K, Idrees MT, Colecchia M, Ulbright TM, Acosta AM. β -Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis. Histopathology. 2024 Jul;85(1):75-80. doi: 10.1111/his.15175. Epub 2024 Mar 26. PMID: 38530207.
- 25: Raju SA, Greenaway EA, Schieppatti A, Arpa G, Vecchione N, Jian C, Grobler C, Maregatti M, Green O, Bowker-Howell FJ, Shiha MG, Penny HA, Cross SS, Ciacci C, Rostami K, Ahmadipour S, Moradi A, Rostami-Nejad M, Biagi F, Volta U, Fiorentino M, Lebowitz B, Green PH, Lewis S, Molina-Infante J, Mata-Romero P, Vaira V, Elli L, Soykan I, Ensari A, Sanders DS. New entity of adult ultra-short coeliac disease: the first international cohort and case-control study. Gut. 2024 Jun 6;73(7):1124-1130. doi: 10.1136/gutjnl-2023-330913. PMID: 38499339.
- 26: Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Ricci C, Fiorentino M, Tallini G, De Biase D, Massari F. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis. Pathol Res Pract. 2024

Feb;254:155142. doi: 10.1016/j.prp.2024.155142. Epub 2024 Jan 17. PMID: 38277752.

27: Ricci C, Ambrosi F, Grillini A, Massari F, Fiorentino M, Colecchia M, Ulbright TM, Acosta AM. Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation. Virchows Arch. 2024 Apr;484(4):709-713. doi: 10.1007/s00428-023-03725-0. Epub 2023 Dec 23. PMID: 38141134.

28: Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase D, Massari F. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. Pathol Res Pract. 2024 Jan;253:155008. doi: 10.1016/j.prp.2023.155008. Epub 2023 Dec 8. PMID: 38103361.

29: Destefanis N, Fiano V, Milani L, Vasapolli P, Fiorentino M, Giunchi F, Lianas L, Del Rio M, Frexia F, Pireddu L, Molinaro L, Cassoni P, Papotti MG, Gontero P, Callaris G, Oderda M, Ricardi U, Iorio GC, Fariselli P, Isaevska E, Akre O, Zelic R, Pettersson A, Zugna D, Richiardi L. Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort. Front Oncol. 2023 Oct 6;13:1242639. doi: 10.3389/fonc.2023.1242639. PMID: 37869094; PMCID: PMC10587560.

30: Ricci C, Ambrosi F, Franceschini T, Giunchi F, Grillini A, Franchini E, Grillini M, Schiavina R, Massari F, Mollica V, Tateo V, Bianchi FM, Bianchi L, Droghetti M, Maloberti T, Tallini G, Colecchia M, Acosta AM, Lobo J, Trpkov K, Fiorentino M, de Biase D. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Arch. 2023 Nov;483(5):687-698. doi: 10.1007/s00428-023-03673-9. Epub 2023 Oct 17. PMID: 37845471; PMCID: PMC10673759.

31: Gaudiano C, Mottola M, Bianchi L, Corcioni B, Braccischi L, Tomassoni MT, Cattabriga A, Cocozza MA, Giunchi F, Schiavina R, Fanti S, Fiorentino M, Brunocilla E, Mosconi C, Bevilacqua A. An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre

Experience. Cancers (Basel). 2023 Jun 30;15(13):3438. doi:

10.3390/cancers15133438. PMID: 37444548; PMCID: PMC10340607.

32: Gaudio C, Renzetti B, De Fino C, Corcioni B, Ciccarese F, Bianchi L, Schiavina R, Droghetti M, Giunchi F, Brunocilla E, Fiorentino M. Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge. Front Oncol. 2023 Jun 5;13:1178430. doi: 10.3389/fonc.2023.1178430. PMID: 37342186; PMCID: PMC10277616.

33: Ricci C, Ambrosi F, Franceschini T, Giunchi F, Di Filippo G, Franchini E, Massari F, Mollica V, Tateo V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M. FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type. Histopathology. 2023 Sep;83(3):465-476. doi: 10.1111/his.14968. Epub 2023 Jun 14. PMID: 37317674.

34: Maloberti T, De Leo A, Coluccelli S, Sanza V, Gruppioni E, Altimari A, Zagnoni S, Giunchi F, Vasuri F, Fiorentino M, Mollica V, Ferrari S, Miccoli S, Visani M, Turchetti D, Massari F, Tallini G, de Biase D. Multi-Gene Next-Generation Sequencing Panel for Analysis of *BRCA1* and *BRCA2* and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci. 2023 May 18;24(10):8940. doi: 10.3390/ijms24108940. PMID: 37240284; PMCID: PMC10219522.

35: Ricci C, Dika E, Corti B, Lambertini M, Ambrosi F, Cappilli S, Grillini M, Filippo GD, Franchini E, Maloberti T, Fiorentino M, Tallini G, Biase D. "Paradoxical" p16 overexpression in cutaneous melanoma: Molecular and immunohistochemical analysis of a rare phenomenon with a focus on cell cycle regulatory molecules. Pathol Res Pract. 2023 Jul;247:154564. doi: 10.1016/j.prp.2023.154564. Epub 2023 May 23. PMID: 37235909.

36: Melotti S, Ambrosi F, Franceschini T, Giunchi F, Filippo GD, Franchini E, Massari F, Mollica V, Tateo V, Bianchi FM, Colecchia M, Acosta AM, Lobo J, Fiorentino M, Ricci C. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis. Pathol Res Pract. 2023 Jul;247:154540. doi: 10.1016/j.prp.2023.154540. Epub 2023 May 18. PMID: 37209574.

37: Iyer HS, Vasekiv JB, Stopsack KH, Roscoe C, DeVille NV, Zhang Y, Penney KL,

Balk SP, Fiorentino M, Hart JE, James P, De Vivo I, Mucci LA, Laden F, Rebbeck TR. Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals. Am J Epidemiol. 2023 Sep 1;192(9):1485-1498. doi: 10.1093/aje/kwad112. PMID: 37139568; PMCID: PMC10948945.

38: Piazza P, Bianchi L, Fiorentino M, Gaudiano C, Giunchi F, Brunocilla E, Schiavina R. The new classification of renal cell carcinoma: what is the clinical issue? Minerva Urol Nephrol. 2023 Jun;75(3):269-271. doi: 10.23736/S2724-6051.23.05293-X. Epub 2023 Mar 22. PMID: 36946718.

39: Ricci C, Altavilla MV, Corti B, Pasquini E, Presutti L, Baietti AM, Amorosa L, Balbi T, Baldovini C, Ambrosi F, Grillini M, D'Errico A, Fiorentino M, Foschini MP. PRAME Expression in Mucosal Melanoma of the Head and Neck Region. Am J Surg Pathol. 2023 May 1;47(5):599-610. doi: 10.1097/PAS.0000000000002032. Epub 2023 Mar 13. PMID: 36912431; PMCID: PMC10101133.

40: Gaudiano C, Braccischi L, Taninokuchi Tomassoni M, Paccapelo A, Bianchi L, Corcioni B, Ciccarese F, Schiavina R, Droghetti M, Giunchi F, Fiorentino M, Brunocilla E, Golfieri R. Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging. Front Oncol. 2023 Feb 20;13:1082564. doi: 10.3389/fonc.2023.1082564. PMID: 36890814; PMCID: PMC9986422.

41: Ricci C, Ambrosi F, Franceschini T, Giunchi F, Maracci ME, Sirolli M, Orsatti A, Chiarucci F, Franchini E, Borsato M, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M. H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma. Pathol Res Pract. 2023 Feb;242:154337. doi: 10.1016/j.prp.2023.154337. Epub 2023 Jan 24. PMID: 36706585.

42: Gaudiano C, Mottola M, Bianchi L, Corcioni B, Cattabriga A, Coccozza MA, Palmeri A, Coppola F, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Golfieri R, Bevilacqua A. Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions. Cancers (Basel). 2022 Dec 14;14(24):6156. doi: 10.3390/cancers14246156. PMID: 36551642; PMCID: PMC9776977.

- 43: Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini MS, Scalambra L, Altamari A, Gruppioni E, Fiorentino M, Giunchi F, Ferracin M, Astolfi A, Indio V, Ardizzoni A, Gelsomino F, Nanni P, Lollini PL, Palladini A. ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. Transl Lung Cancer Res. 2022 Nov;11(11):2216-2229. doi: 10.21037/tlcr-22-163. PMID: 36519016; PMCID: PMC9742620.
- 44: Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. Mol Cancer Res. 2023 Mar 1;21(3):253-260. doi: 10.1158/1541-7786.MCR-22-0627. PMID: 36511902; PMCID: PMC9991973.
- 45: Marchese PV, Mollica V, Tassinari E, De Biase D, Giunchi F, Marchetti A, Rosellini M, Fiorentino M, Massari F. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. Expert Rev Mol Diagn. 2022 Nov;22(11):997-1008. doi: 10.1080/14737159.2022.2154148. Epub 2022 Dec 12. PMID: 36503370.
- 46: Ricci C, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Mollica V, Bianchi FM, Colecchia M, Acosta AM, Fiorentino M. Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1...but choriocarcinoma? Pathol Res Pract. 2023 Jan;241:154269. doi: 10.1016/j.prp.2022.154269. Epub 2022 Dec 7. PMID: 36502737.
- 47: Droghetti M, Bianchi L, Beretta C, Balestrazzi E, Costa F, Feruzzi A, Piazza P, Roveroni C, Gaudiano C, Corcioni B, Giunchi F, Fiorentino M, Golfieri R, Schiavina R, Brunocilla E. Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap? World J Urol. 2023 Jan;41(1):27-33. doi: 10.1007/s00345-022-04229-3. Epub 2022 Dec 5. PMID: 36471133.
- 48: Ercolino A, Manes F, Vasuri F, Bianchi L, Garofalo M, Piazza P, Corcioni B, Schiavina R, Golfieri R, Fiorentino M, Colecchia M, Brunocilla E. A case report of myoid gonadal stromal tumor treated with testis sparing surgery. Transl Androl Urol. 2022 Oct;11(10):1458-1465. doi: 10.21037/tau-22-179. PMID: 36386257; PMCID: PMC9641068.

49: Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. J Exp Clin Cancer Res. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. PMID: 36245005; PMCID: PMC9575294.

50: Stopsack KH, Su XA, Vasselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, Mucci LA. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. Mol Cancer Res. 2023 Jan 3;21(1):14-23. doi: 10.1158/1541-7786.MCR-22-0446. PMID: 36125519; PMCID: PMC9812892.

51: Orsatti A, Sirolli M, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Grillini M, Massari F, Mollica V, Bianchi FM, Colecchia M, Fiorentino M, Ricci C. SOX2 and PRAME in the "reprogramming" of seminoma cells. Pathol Res Pract. 2022 Sep;237:154044. doi: 10.1016/j.prp.2022.154044. Epub 2022 Jul 28. PMID: 35930824.

52: Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. PMID: 35895872; PMCID: PMC9627128.

53: Droghetti M, Bianchi L, Gaudiano C, Corcioni B, Rustici A, Piazza P, Beretta C, Balestrazzi E, Costa F, Feruzzi A, Salvador M, Giunchi F, Fiorentino M, Golfieri R, Schiavina R, Brunocilla E. Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters. Minerva Urol Nephrol. 2023 Feb;75(1):42-49. doi: 10.23736/S2724-6051.22.04932-1. Epub 2022 Jun 29. PMID: 35766364.

54: Marchese PV, Mollica V, De Biase D, Giunchi F, Tassinari E, Marchetti A, Rosellini M, Nuvola G, Maloberti T, Fiorentino M, Massari F. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy. Pathol Res Pract. 2022 Aug;236:153983. doi: 10.1016/j.prp.2022.153983. Epub 2022 Jun 13. PMID: 35751929.

55: Di Sciascio L, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Bianchi FM, Colecchia M, Fiorentino M, Ricci C. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions? Pathol Res Pract. 2022 Jun;234:153937. doi: 10.1016/j.prp.2022.153937. Epub 2022 May 6. PMID: 35561522.

56: Ambrosi F, Giunchi F, Capizzi E, Cancellieri A, Trisolini R, Ardizzoni A, Fiorentino M, Ricci C. Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples. Pathol Res Pract. 2022 May;233:153893. doi: 10.1016/j.prp.2022.153893. Epub 2022 Apr 12. PMID: 35429890.

57: Ricci C, Dika E, Lambertini M, Ambrosi F, Grillini M, Chillotti S, Corradini AG, Veronesi G, Fiorentino M, Corti B. Hematoxylin and eosin or double stain for CD34/SOX10: Which is better for the detection of lymphovascular invasion in cutaneous melanoma? Pathol Res Pract. 2022 May;233:153876. doi: 10.1016/j.prp.2022.153876. Epub 2022 Apr 1. PMID: 35390633.

58: Ricci C, Dika E, Lambertini M, Ambrosi F, Chiarucci F, Chillotti S, Fiorentino M, Fabbri E, Tassone D, Veronesi G, Tartari F, Corti B. The EORTC protocol for sentinel lymph node biopsy (SLNB) reveals a high number of nodal nevi and a strong association with nevus-associated melanoma. Pathol Res Pract. 2022 May;233:153805. doi: 10.1016/j.prp.2022.153805. Epub 2022 Mar 28. PMID: 35361504.

59: Gaudio C, Ciccarese F, Bianchi L, Corcioni B, De Cinque A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Golfieri R. The role of MRI in the detection of local recurrence: Added value of multiparametric approach and Signal Intensity/Time Curve analysis. Arch Ital Urol Androl. 2022 Mar 28;94(1):25-31. doi: 10.4081/aiua.2022.1.25. PMID: 35352521.

60: Mazzeschi M, Sgarzi M, Romaniello D, Gelfo V, Cavallo C, Ambrosi F, Morselli

A, Miano C, Laprovitera N, Girone C, Ferracin M, Santi S, Rihawi K, Ardizzoni A, Fiorentino M, D'Uva G, Györfy B, Palmer R, Lauriola M. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. J Exp Clin Cancer Res. 2022 Mar 29;41(1):113. doi: 10.1186/s13046-022-02309-1. PMID: 35351152; PMCID: PMC8962179.

61: Cambuli F, Foletto V, Alaimo A, De Felice D, Gandolfi F, Palumbieri MD, Zaffagni M, Genovesi S, Lorenzoni M, Celotti M, Bertossio E, Mazzero G, Bertossi A, Bisio A, Berardinelli F, Antoccia A, Gaspari M, Barbareschi M, Fiorentino M, Shen MM, Loda M, Romanel A, Lunardi A. Intra-epithelial non-canonical Activin A signaling safeguards prostate progenitor quiescence. EMBO Rep. 2022 May 4;23(5):e54049. doi: 10.15252/embr.202154049. Epub 2022 Mar 7. PMID: 35253958; PMCID: PMC9066067.

62: Zelic R, Giunchi F, Fridfeldt J, Carlsson J, Davidsson S, Lianas L, Mascia C, Zugna D, Molinaro L, Vincent PH, Zanetti G, Andrén O, Richiardi L, Akre O, Fiorentino M, Pettersson A. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clin Epidemiol. 2022 Jan 18;14:59-70. doi: 10.2147/CLEP.S339140. PMID: 35082531; PMCID: PMC8784949.

63: Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vasselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife. 2021 Dec 23;10:e71265. doi: 10.7554/eLife.71265. PMID: 34939926; PMCID: PMC8849344.

64: Gaudiano C, Rustici A, Corcioni B, Ciccarese F, Bianchi L, Schiavina R, Giunchi F, Fiorentino M, Brunocilla E, Golfieri R. PI-RADS version 2.1 for the evaluation of transition zone lesions: a practical guide for radiologists. Br J Radiol. 2022 Mar 1;95(1131):20210916. doi: 10.1259/bjr.20210916. Epub 2022 Feb 11. PMID: 34919421; PMCID: PMC8978244.

65: AACR Pathology Task Force. Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology. Clin Cancer Res. 2022 Jan 15;28(2):265-270. doi: 10.1158/1078-0432.CCR-21-1206. Epub 2021 Dec 10. PMID: 34893516.

66: Dorofte L, Grélaud D, Fiorentino M, Giunchi F, Ricci C, Franceschini T, Riefolo M, Davidsson S, Carlsson J, Lillsunde Larsson G, Karlsson MG. Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care. Virchows Arch. 2022 Apr;480(4):879-886. doi: 10.1007/s00428-021-03249-5. Epub 2021 Dec 10. PMID: 34889977; PMCID: PMC9023398.

67: Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F, Mollica V, Colecchia M, Fiorentino M. Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis. Am J Clin Pathol. 2022 May 4;157(5):644-648. doi: 10.1093/ajcp/aqab200. PMID: 34864837.

68: De Maglio G, Pasello G, Dono M, Fiorentino M, Follador A, Sciortino M, Malapelle U, Tiseo M. The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. Crit Rev Oncol Hematol. 2022 Jan;169:103561. doi: 10.1016/j.critrevonc.2021.103561. Epub 2021 Nov 29. PMID: 34856311.

69: Gaudiano C, Bianchi L, De Cinque A, Corcioni B, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Golfieri R. The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors. Radiol Med. 2022 Feb;127(2):174-182. doi: 10.1007/s11547-021-01433-w. Epub 2021 Nov 30. PMID: 34850354.

70: Gaudiano C, Bianchi L, Corcioni B, Giunchi F, Schiavina R, Ciccarese F, Braccischi L, Rustici A, Fiorentino M, Brunocilla E, Golfieri R. Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones. Int Urol Nephrol. 2022 Feb;54(2):263-271. doi: 10.1007/s11255-021-03071-7. Epub 2021 Nov 25. PMID: 34822065.

71: Ricci C, Franceschini T, Giunchi F, Borsato M, Mollica V, Massari F, Fiorentino M. A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. Pathol Res Pract. 2021 Nov;227:153637. doi: 10.1016/j.prp.2021.153637. Epub 2021 Sep 29. PMID: 34619577.

72: Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Semin Cancer Biol. 2022 Nov;86(Pt 3):1058-1065. doi: 10.1016/j.semcancer.2021.09.007. Epub 2021 Sep 15. PMID: 34536504.

73: Grillini M, Ricci C, Pino V, Pedrini S, Fiorentino M, Corti B. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME). Appl Immunohistochem Mol Morphol. 2022 Jan 1;30(1):14-18. doi: 10.1097/PAI.0000000000000972. PMID: 34508017; PMCID: PMC9575561.

74: Ricci AD, Rizzo A, Mollica V, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. Anticancer Drugs. 2022 Jan 1;33(1):e61-e68. doi: 10.1097/CAD.0000000000001200. PMID: 34387596.

75: Davidsson S, Fiorentino M, Giunchi F, Eriksson M, Erlandsson A, Sundqvist P, Carlsson J. Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma. Eur Urol Open Sci. 2020 Aug 20;20:62-71. doi: 10.1016/j.euros.2020.06.003. PMID: 34337459; PMCID: PMC8317874.

76: Bianchi L, Chessa F, Angiolini A, Cercenelli L, Lodi S, Bortolani B, Molinaroli E, Casablanca C, Droghetti M, Gaudiano C, Mottaran A, Porreca A, Golfieri R, Romagnoli D, Giunchi F, Fiorentino M, Piazza P, Puliatti S, Diciotti S, Marcelli E, Mottre A, Schiavina R. The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy. Eur Urol. 2021 Oct;80(4):480-488. doi: 10.1016/j.eururo.2021.06.020. Epub 2021 Jul 29. PMID: 34332759.

77: Sbravati F, Cosentino A, Lenzi J, Fiorentino M, Ambrosi F, Salerno A, Di Biase A, Righi B, Brusa S, Valin PS, Bruni L, Battistini B, Pagano S, Grondona AG, Labriola F, Alvisi P. Antitissue transglutaminase antibodies' normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience. Dig Liver Dis. 2022 Mar;54(3):336-342. doi: 10.1016/j.dld.2021.06.026. Epub 2021 Jul 14. PMID: 34274255.

- 78: Zanoni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, Matti A, Schiavina R, Fiorentino M, Romagnoli D, Fonti C, Lodi F, D'Errico A, Brunocilla E, Porreca A, Fanti S. [¹⁸F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. *Eur J Nucl Med Mol Imaging*. 2021 Dec;49(1):390-409. doi: 10.1007/s00259-021-05429-6. Epub 2021 Jul 2. PMID: 34213609.
- 79: Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? *Int J Mol Sci*. 2021 Jun 9;22(12):6237. doi: 10.3390/ijms22126237. PMID: 34207825; PMCID: PMC8226484.
- 80: Ricci C, Ambrosi F, Dika E, Lambertini M, Chillotti S, Fiorentino M, Corti B. Giant (pseudo) vascular spiradenoma: a case report of an extremely rare entity with the immuno-histological demonstration of the coexistence of vascular and pseudo-vascular components. *Ital J Dermatol Venerol*. 2021 Oct;156(5):630-632. doi: 10.23736/S2784-8671.21.06883-8. Epub 2021 Apr 23. PMID: 33890732.
- 81: Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. *Pathol Res Pract*. 2021 Jun;222:153440. doi: 10.1016/j.prp.2021.153440. Epub 2021 Apr 9. PMID: 33857854.
- 82: Giunchi F, Franceschini T, Fiorentino M. A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations? *Transl Androl Urol*. 2021 Mar;10(3):1553-1561. doi: 10.21037/tau-20-1185. PMID: 33850789; PMCID: PMC8039592.
- 83: Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, Fiorentino M, Ardizzoni A. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. *Clin Lung Cancer*. 2021 Sep;22(5):423-431. doi: 10.1016/j.clcc.2021.03.005. Epub 2021 Mar

16. PMID: 33849808.

84: Livi V, Paioli D, Cancellieri A, Betti S, Natali F, Ferrari M, Fiorentino M, Trisolini R. Diagnosis and Molecular Profiling of Lung Cancer by Percutaneous Ultrasound-Guided Biopsy of Superficial Metastatic Sites Is Safe and Highly Effective. Respiration. 2021;100(6):515-522. doi: 10.1159/000514316. Epub 2021 Apr 7. PMID: 33827098.

85: Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, Fiorentino M, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S. The Role of [¹⁸F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [¹¹C]Choline PET/CT and Histopathological Analysis. Cancers (Basel). 2021 Mar 29;13(7):1575. doi: 10.3390/cancers13071575. PMID: 33805543; PMCID: PMC8037300.

86: Pantaleo MA, Mandruzzato M, Indio V, Urbini M, Nannini M, Gatto L, Schipani A, Fiorentino M, Franceschini T, Ambrosini V, Di Scioscio V, Saponara M, Ianni M, Concetti S, Altimari A, Ardizzoni A, Astolfi A. Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling. Front Oncol. 2021 Mar 16;11:633543. doi: 10.3389/fonc.2021.633543. PMID: 33796464; PMCID: PMC8008106.

87: Borghesi M, Bianchi L, Barbaresi U, Vagnoni V, Corcioni B, Gaudiano C, Fiorentino M, Giunchi F, Chessa F, Garofalo M, Bertaccini A, Angelini S, Ercolino A, Casablanca C, Droghetti M, Golfieri R, Schiavina R. Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance. Minerva Urol Nephrol. 2021 Jun;73(3):357-366. doi: 10.23736/S2724-6051.20.03758-3. Epub 2021 Mar 26. PMID: 33769008.

88: Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F. Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. Pathol Res Pract. 2021 Apr;220:153410. doi: 10.1016/j.prp.2021.153410. Epub 2021 Mar 18. PMID: 33765474.

89: Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, Fiorentino M, Giunchi F, Massari F. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. Pathol Res Pract. 2021 Mar;219:153350. doi: 10.1016/j.prp.2021.153350. Epub 2021 Feb 1. PMID: 33556910.

90: Zelic R, Giunchi F, Lianas L, Mascia C, Zanetti G, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Molinaro L, Vincent PH, Richiardi L, Akre O, Fiorentino M, Pettersson A. Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. Sci Rep. 2021 Feb 5;11(1):3257. doi: 10.1038/s41598-021-82911-z. PMID: 33547336; PMCID: PMC7864946.

91: Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, Fiorentino M, Massari F. Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. Diagnostics (Basel). 2021 Jan 28;11(2):184. doi: 10.3390/diagnostics11020184. PMID: 33525402; PMCID: PMC7910958.

92: Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, Fiorentino M, Ebot EM, Mucci LA. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):751-756. doi: 10.1158/1055-9965.EPI-20-1461. Epub 2021 Jan 26. PMID: 33500320; PMCID: PMC8132456.

93: Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A. Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. Diagnostics (Basel). 2020 Dec 20;10(12):1109. doi: 10.3390/diagnostics10121109. PMID: 33419298; PMCID: PMC7765862.

94: Ricci C, Capizzi E, Giunchi F, Casolari L, Gelsomino F, Rihawi K, Natali F, Livi V, Trisolini R, Fiorentino M, Ardizzoni A. Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. Ther Adv Med Oncol. 2020 Nov 30;12:1758835920954802. doi: 10.1177/1758835920954802. PMID: 33299472; PMCID: PMC7711224.

95: Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M,

Brunocilla E, Ardizzoni A, Massari F. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anticancer Drugs. 2021 Jan 1;32(1):74-81. doi: 10.1097/CAD.0000000000001017. PMID: 33290315.

96: Schiavina R, Droghetti M, Novara G, Bianchi L, Gaudiano C, Panebianco V, Borghesi M, Piazza P, Mineo Bianchi F, Guerra M, Corcioni B, Fiorentino M, Giunchi F, Verze P, Pultrone C, Golfieri R, Porreca A, Mirone V, Brunocilla E. The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. Urol Oncol. 2021 Jul;39(7):433.e1-433.e7. doi: 10.1016/j.urolonc.2020.10.018. Epub 2020 Nov 13. PMID: 33191117.

97: Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, Fiorentino M, Umeton R, Loda M. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021 Mar;19(3):475-484. doi: 10.1158/1541-7786.MCR-20-0548. Epub 2020 Nov 9. PMID: 33168599; PMCID: PMC8369519.

98: Sirri R, Tura G, Budai J, Beraldo P, Fiorentino M, Barbé T, Galeotti M, Sarli G, Mandrioli L. Histological and immunohistochemical characterization of 17 gonadal tumours in koi carp (Cyprinus carpio koi). J Fish Dis. 2021 Mar;44(3):273-285. doi: 10.1111/jfd.13280. Epub 2020 Oct 24. PMID: 33098685.

99: Dall'Olio FG, Conci N, Rossi G, Fiorentino M, De Giglio A, Grilli G, Altimari A, Gruppioni E, Filippini DM, Di Federico A, Nuvola G, Ardizzoni A. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience. Lung Cancer. 2020 Nov;149:5-9. doi: 10.1016/j.lungcan.2020.08.008. Epub 2020 Sep 3. PMID: 32932213.

100: Damiani S, Fiorentino M, De Palma A, Foschini MP, Lazzarotto T, Gabrielli L, Viale PL, Attard L, Riefolo M, D'Errico A. Pathological post-mortem findings in lungs infected with SARS-CoV-2. J Pathol. 2021 Jan;253(1):31-40. doi: 10.1002/path.5549. Epub 2020 Nov 4. PMID: 32930394.

101: Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng

L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is There a Role for Immunotherapy in Prostate Cancer? Cells. 2020 Sep 8;9(9):2051. doi: 10.3390/cells9092051. PMID: 32911806; PMCID: PMC7564598.

102: Schiavina R, Bianchi L, Lodi S, Cercenelli L, Chessa F, Bortolani B, Gaudiano C, Casablanca C, Droghetti M, Porreca A, Romagnoli D, Golfieri R, Giunchi F, Fiorentino M, Marcelli E, Diciotti S, Brunocilla E. Real-time Augmented Reality Three-dimensional Guided Robotic Radical Prostatectomy: Preliminary Experience and Evaluation of the Impact on Surgical Planning. Eur Urol Focus. 2021 Nov;7(6):1260-1267. doi: 10.1016/j.euf.2020.08.004. Epub 2020 Sep 1. PMID: 32883625.

103: Ambrosi F, Ricci C, Malvi D, Cillia C, Ravaioli M, Fiorentino M, Cardillo M, Vasuri F, D'Errico A. Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors. Kidney Res Clin Pract. 2020 Dec 31;39(4):487-494. doi: 10.23876/j.krcp.20.050. PMID: 32855366; PMCID: PMC7770991.

104: Lamberti G, Gelsomino F, Brocchi S, Poerio A, Melotti B, Sperandi F, Gargiulo M, Borghi C, Fiorentino M, Ardizzoni A. New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Ther Adv Med Oncol. 2020 Jul 24;12:1758835920913801. doi: 10.1177/1758835920913801. PMID: 32782484; PMCID: PMC7383634.

105: Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 Sep;20(9):755-763. doi: 10.1080/14737140.2020.1807334. Epub 2020 Aug 16. PMID: 32757789.

106: Colecchia M, Bertolotti A, Paolini B, Giunchi F, Necchi A, Paganoni AM, Ricci C, Fiorentino M, Dagrada GP. The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification. Histopathology. 2021 Jan;78(2):290-299. doi: 10.1111/his.14225. Epub 2020 Sep 24. PMID: 32757426.

107: Trisolini R, Cancellieri A, Livi V, Annema JT, Ferrari M, Natali F, Paioli

D, Conci N, Altimari A, Fiorentino M, Ardizzoni A. Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations. Lung Cancer. 2020 Sep;147:204-208. doi: 10.1016/j.lungcan.2020.07.025. Epub 2020 Jul 26. PMID: 32736279.

108: Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, Grossi F, Fiorentino M, Ardizzoni A. Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histologic Subtypes (CHANCE trial). Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983. PMID: 32733604; PMCID: PMC7372524.

109: Franceschini T, Capizzi E, Massari F, Schiavina R, Fiorentino M, Giunchi F. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. Pathol Res Pract. 2020 Aug;216(8):153012. doi: 10.1016/j.prp.2020.153012. Epub 2020 May 24. PMID: 32703487.

110: Ricci C, Ambrosi F, Grillini M, Serra M, Melotti B, Gruppioni E, Altimari A, Fiorentino M, Dika E, Lambertini M, Corti B. Next-generation sequencing revealing TP53 mutation as potential genetic driver in dermal deep-seated melanoma arising in giant congenital nevus in adult patients: A unique case report and review of the literature. J Cutan Pathol. 2020 Dec;47(12):1164-1169. doi: 10.1111/cup.13802. Epub 2020 Aug 11. PMID: 32643812.

111: Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020 Oct;78(4):637-639. doi: 10.1016/j.eururo.2020.05.035. Epub 2020 Jul 3. PMID: 32624279; PMCID: PMC8411278.

112: Droghetti M, Ercolino A, Piazza P, Bianchi L, Fabbrizio B, Giunchi F, Mineo Bianchi F, Barbaresi U, Casablanca C, Tonin E, Mottaran A, Fiorentino M, Schiavina R, Brunocilla E. Secondary bladder amyloidosis due to Crohn's disease: a case report and literature review. CEN Case Rep. 2020 Nov;9(4):413-417. doi:

10.1007/s13730-020-00497-3. Epub 2020 Jun 22. PMID: 32572782; PMCID: PMC7502084.

113: Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020 Jul 14;41(7):904-908. doi: 10.1093/carcin/bgaa061. PMID: 32556091; PMCID: PMC7359768.

114: Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, Fiorentino M, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers (Basel). 2020 Jun 2;12(6):1449. doi: 10.3390/cancers12061449. PMID: 32498352; PMCID: PMC7352972.

115: Natali F, Cancellieri A, Giunchi F, De Silvestri A, Livi V, Ferrari M, Paioli D, Betti S, Fiorentino M, Trisolini R. Interobserver agreement between pathologist, pulmonologist and molecular pathologist to estimate the tumour burden in rapid on-site evaluation smears from endosonography and guided bronchoscopy. Cytopathology. 2020 Jul;31(4):303-309. doi: 10.1111/cyt.12867. PMID: 32463969.

116: Minari R, Mazzaschi G, Bordi P, Gnetti L, Alberti G, Altimari A, Gruppioni E, Sperandi F, Parisi C, Guaitoli G, Bettelli S, Longo L, Bertolini F, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, Fiorentino M, Tiseo M; DETECTION Study Group. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clin Lung Cancer. 2020 Sep;21(5):e464-e473. doi: 10.1016/j.clcc.2020.02.021. Epub 2020 Mar 9. PMID: 32276870.

117: Junker K, Eckstein M, Fiorentino M, Montironi R. PD1/PD-L1 Axis in Uro-oncology. Curr Drug Targets. 2020;21(13):1293-1300. doi: 10.2174/1389450121666200326123700. PMID: 32213156.

118: Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, Giovannetti E, Fiorentino M, Tiseo M, Petronini PG, Ardizzoni A. Pemetrexed Enhances Membrane PD-L1 Expression and

Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 12;12(3):666. doi: 10.3390/cancers12030666. Erratum in: Cancers (Basel). 2025 Apr 08;17(8):1254. doi: 10.3390/cancers17081254. PMID: 32178474; PMCID: PMC7139811.

119: Calìo A, Brunelli M, Segala D, Pedron S, Remo A, Ammendola S, Munari E, Pierconti F, Mosca A, Bollito E, Sidoni A, Fisogni S, Sacco C, Canu L, Sentinelli S, Fraccon AP, Fiorentino M, Scott C, Milella M, Porta C, Argani P, Martignoni G. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology. 2020 Apr;52(3):297-309. doi: 10.1016/j.pathol.2019.11.006. Epub 2020 Feb 24. PMID: 32107074.

120: Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, Fiorentino M. Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. Diagnostics (Basel). 2020 Feb 23;10(2):123. doi: 10.3390/diagnostics10020123. PMID: 32102250; PMCID: PMC7168142.

121: Dika E, Veronesi G, Altimari A, Riefolo M, Ravaioli GM, Piraccini BM, Lambertini M, Campione E, Gruppioni E, Fiorentino M, Melotti B, Ferracin M, Patrizi A. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. Am J Clin Pathol. 2020 Apr 15;153(5):664-671. doi: 10.1093/ajcp/aqz209. PMID: 32017841.

122: Gatto L, Del Gaudio M, Ravaioli M, Cescon M, Tonini V, Cervellera M, Franceschelli A, Pirini MG, Di Scioscio V, Buia F, Niro F, Capizzi E, Fiorentino M, Astolfi A, Indio V, Nannini M, Pantaleo MA, Saponara M. Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. Integr Cancer Ther. 2020 Jan-Dec;19:1534735419900554. doi: 10.1177/1534735419900554. PMID: 32009477; PMCID: PMC7050957.

123: Giunchi F, Gevaert T, Scarpelli M, Fiorentino M. Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms. Curr Drug Targets. 2020;21(13):1286-1292. doi: 10.2174/1389450121666200123124642. PMID: 31971109.

124: Dika E, Lambertini M, Patrizi A, Misciali C, Altimari A, Fiorentino M, Melotti B, Corti B, Riefolo M, Veronesi G. Frequency of somatic mutations in head and neck melanoma: A single-institution experience. Pigment Cell Melanoma Res. 2020 May;33(3):515-517. doi: 10.1111/pcmr.12864. Epub 2020 Jan 27. PMID: 31945266.

Native language(s)

Italian

Other languages) Self-evaluation

English

English

Comprehension	Spoken	Written							
		Ascolto	Lettura	Interazione orale	Produzione orale				
			C2		C2		C2		C2

Organizing skill

Chief of Diagnostic Laboratory Unit since 2008.
Associate director of Molecular pathology laboratory in the United States
Certificate of managing for the direction of complex health structures within the Italian Health Service
Director of Pathology Service since 2019

IT skills

Good knowledge of Word processor, Excel, Power-Point, Access

Driving License

B

Firma

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

